Intellia Therapeutics(us:NTLA)
6.66
-6.33%
Updated on 2025-04-02
Open:7.08
Close:6.66
High:7.14
Low:6.59
Prev Close:7.11
Volume:5.08M
Turnover:34.50M
Turnover Ratio:4.91%
Shares:103.52M
MarketCap:688.91M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 318 | 89942861 | 91.51% | 45 | 111 | 123 |
| 2024-03-31 | 315 | 90602810 | 94.05% | 37 | 114 | 127 |
| 2023-12-31 | 321 | 85224411 | 91.64% | 49 | 121 | 112 |
| 2023-09-30 | 308 | 79470991 | 89.19% | 33 | 118 | 100 |
| 2023-06-30 | 312 | 77428982 | 87.64% | 35 | 102 | 106 |
| 2023-03-31 | 320 | 77929623 | 88.46% | 31 | 104 | 132 |
| 2022-12-31 | 358 | 77979141 | 89.53% | 50 | 117 | 141 |
| 2022-09-30 | 341 | 67357543 | 87.95% | 49 | 109 | 124 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Ark Investment Management Llc | 11595789 | 11.80% | 606507 | 5.52% |
| 2024-06-30 | Blackrock Inc. | 9597607 | 9.76% | 488339 | 5.36% |
| 2024-06-30 | Vanguard Group Inc | 9100068 | 9.26% | 6356 | 0.07% |
| 2024-06-30 | Deep Track Capital, Lp | 4800000 | 4.88% | 589216 | 13.99% |
| 2024-06-30 | State Street Corp | 4362780 | 4.44% | -235042 | -5.11% |
| 2024-06-30 | Nikko Asset Management Americas, Inc. | 3257689 | 3.31% | -141629 | -4.17% |
| 2024-06-30 | Sumitomo Mitsui Trust Holdings, Inc. | 3257689 | 3.31% | -141629 | -4.17% |
| 2024-06-30 | Morgan Stanley | 2337709 | 2.38% | -307142 | -11.61% |
| 2024-06-30 | Federated Hermes, Inc. | 2300889 | 2.34% | 371189 | 19.24% |
| 2024-06-30 | Geode Capital Management, Llc | 2293943 | 2.33% | 249686 | 12.21% |
About
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Address:40 Erie Street,Suite 130
Website:http://www.intelliatx.com
Market Movers